SUMMARY: Globalizing precision oncology should be a major priority for cancer care in the upcoming decades. In this issue, the K-MASTER study provides a framework for infrastructure building in East Asia illustrating the widening global potential of precision oncology. It is time to modify the precision oncology mantra: Give the right drug, to the right patient, at the right time in every country, to think globally and act locally. See related article by Park et al., p. 938 (3).
No takes yet. Share an insight, caveat, or question.
Moyers et al. (2022) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: